Journal of Clinical & Experimental Pharmacology

Abstract

Treatment of Post-menopausal Osteoporosis by Strontium Ranelate in Everyday Practice – DUAL Study

Juraj Payer, Peter Vanuga, Zdenko Killinger, Sona Tomkova and Peter Jackuliak

Abstract: Introduction: Strontium ranelate (SR) is an effective modality for treatment of postmenopausal osteoporosis. Its effectiveness and acceptability was proven in large phase III trials SOTI and TROPOS and its evaluation in real everyday practice deserves to be more investigated. The objective of the presented study was to evaluate the satisfaction of SR treatment by the patients and to assess the effect of treatment on quality of life and the compliance to SR in every-day practice. Methods: Study, called DUAL was a one-year prospective open multicentric study performed in rheumatology, endocrinology and orthopedic practices in Slovakia. In total 190 patients were included in 39 centers. Questionnaire concerning satisfaction with treatment, acceptability of treatment, compliance and quality of life was applied at M0, M3, M6 and M12. At M0 and M12 the hip and lumbar spine BMD measurement was performed. Results: From 190 included patients in total, 85% of them complete the study. Overall satisfaction with treatment as well as with daily intake in form of suspension was around 90% and stable during whole study duration. According to the set of questions regarding the quality of life there is a significant improvement of the overall physical condition and mobility. A strong positive effect on back pain was detected throughout the whole period of study. In 92 patients, BMD at hip level increased by 3.5% (p ≤ 0.05) whereas in 108 patients, BMD at lumbar spine increased by 6.1% (p ≤ 0.01). No cardiovascular adverse event was reported. Conclusions: This study with SR in every-day practice is in accordance with results from phase III trials. The treatment is well accepted and tolerated by patients, leading to a good compliance. Respecting the restriction is the treatment also safe. Efficacy on BMD and benefits on the quality of life, in particular the strong reduction of pain, as soon as after one year could be used as unique opportunities to increase persistence of patients treated with SR to gain full therapeutic effect of the treatment.
Mini-Abstract The DUAL study evaluated the satisfaction of treatment strontium ranelate by the patients and to assess the effect of treatment on quality of life and the compliance with SR in every-day practice. The study confirms that strontium ranelate is an innovative treatment of postmenopausal osteoporosis. The authors confirm that all the research meets the ethical guidelines, including adherence to the legal requirements of Slovakia. We assert that there are no conflicts of interest (both personal and institutional) regarding specific financial interests that are relevant to the work conducted or reported in this manuscript.